Lactobacillus Crispatus Dominant Vaginal Microbiome is Associated with Inhibitory Activity of Female Genital Tract Secretions Against Escherichia Coli
Overview
Authors
Affiliations
Objective: Female genital tract secretions inhibit E. coli ex vivo and the activity may prevent colonization and provide a biomarker of a healthy microbiome. We hypothesized that high E. coli inhibitory activity would be associated with a Lactobacillus crispatus and/or jensenii dominant microbiome and differ from that of women with low inhibitory activity.
Study Design: Vaginal swab cell pellets from 20 samples previously obtained in a cross-sectional study of near-term pregnant and non-pregnant healthy women were selected based on having high (>90% inhibition) or low (<20% inhibition) anti-E. coli activity. The V6 region of the 16S ribosomal RNA gene was amplified and sequenced using the Illumina HiSeq 2000 platform. Filtered culture supernatants from Lactobacillus crispatus, Lactobacillus iners, and Gardnerella vaginalis were also assayed for E. coli inhibitory activity.
Results: Sixteen samples (10 with high and 6 with low activity) yielded evaluable microbiome data. There was no difference in the predominant microbiome species in pregnant compared to non-pregnant women (n = 8 each). However, there were significant differences between women with high compared to low E. coli inhibitory activity. High activity was associated with a predominance of L. crispatus (p<0.007) and culture supernatants from L. crispatus exhibited greater E. coli inhibitory activity compared to supernatants obtained from L. iners or G. vaginalis. Notably, the E. coli inhibitory activity varied among different strains of L. crispatus.
Conclusion: Microbiome communities with abundant L. crispatus likely contribute to the E. coli inhibitory activity of vaginal secretions and efforts to promote this environment may prevent E. coli colonization and related sequelae including preterm birth.
Stojanov S, Plavec T, Zupancic S, Berlec A Microb Cell Fact. 2024; 23(1):333.
PMID: 39696572 PMC: 11657421. DOI: 10.1186/s12934-024-02612-w.
increases HSV-2 infection by decreasing vaginal barrier integrity and increasing inflammation .
Rahman N, Mian M, Hayes C, Nazli A, Kaushic C Front Immunol. 2024; 15:1487726.
PMID: 39650661 PMC: 11621107. DOI: 10.3389/fimmu.2024.1487726.
The Vaginal Microbiome of Transgender and Gender Nonbinary Individuals.
Winston McPherson G, Goldstein Z, Salipante S, Rongitsch J, Hoffman N, Dy G Transgend Health. 2024; 9(3):205-211.
PMID: 39109262 PMC: 11299096. DOI: 10.1089/trgh.2022.0100.
Human vaginal microbiota colonization is regulated by female sex hormones in a mouse model.
Rahman N, Mian M, Nazli A, Kaushic C Front Cell Infect Microbiol. 2023; 13:1307451.
PMID: 38156321 PMC: 10753781. DOI: 10.3389/fcimb.2023.1307451.
Comparison of vaginal microbiota between women with inflammatory bowel disease and healthy controls.
Bar O, Sudhof L, Yockey L, Bergerat A, Moriel N, Andrews E PLoS One. 2023; 18(11):e0284709.
PMID: 38019873 PMC: 10686494. DOI: 10.1371/journal.pone.0284709.